Spero Therapeutics Stock Today
| SPRO Stock | USD 1.13 0.02 1.74% |
Performance0 of 100
| Odds Of DistressLess than 2
|
Spero Therapeutics is selling at 1.13 as of the 28th of November 2024; that is 1.74 percent decrease since the beginning of the trading day. The stock's open price was 1.15. Spero Therapeutics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Spero Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. The company has 54.52 M outstanding shares of which 625.19 K shares are at this time shorted by private and institutional investors with about 2.08 trading days to cover. More on Spero Therapeutics
Moving against Spero Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Spero Stock Highlights
| President | Timothy Keutzer |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Spero Therapeutics (SPRO) is traded on NASDAQ Exchange in USA. It is located in 675 Massachusetts Avenue, Cambridge, MA, United States, 02139 and employs 46 people. Spero Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.61 M. Spero Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.52 M outstanding shares of which 625.19 K shares are at this time shorted by private and institutional investors with about 2.08 trading days to cover.
Spero Therapeutics currently holds about 45.4 M in cash with (32.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Spero Therapeutics Probability Of Bankruptcy
Ownership AllocationSpero Therapeutics shows a total of 54.52 Million outstanding shares. Spero Therapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Spero Ownership Details
Spero Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Spero Therapeutics market risk premium is the additional return an investor will receive from holding Spero Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.67) | |||
| Treynor Ratio | (0.64) |
Spero Stock Against Markets
Spero Therapeutics Corporate Management
| Satyavrat CFA | CFO Treasurer | Profile | |
| James Brady | Chief Officer | Profile | |
| Ted Jenkins | VP Relations | Profile | |
| Ian Critchley | Head Microbiology | Profile | |
| Susannah Walpole | Head Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.